Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Pharmacy Perspectives for Tailoring Hemophilia A Prophylaxis: Review of Current and Evolving Treatments

Credits Available
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 24, 2022 Expiration: May 23, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme
person default
Justin Arnall, PharmD, BCOP
person default
Kayla Douglas, PharmD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement individualized hemophilia A prophylaxis strategies that optimize adherence, outcomes, and utilization of resources
  • Identify patients who are likely to benefit from nonfactor replacement therapy
  • Mitigate complications and barriers to adherence in patients receiving factor replacement therapy
  • Apply recent safety and efficacy data for both factor replacement and nonfactor prophylaxis in hemophilia A to clinical practice
  • Manage comorbidities in patients receiving prophylaxis for hemophilia A
  • Develop a plan to educate the multidisciplinary team, patients, and caregivers on the characteristics, dosing, and administration of novel prophylaxis strategies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Justin Arnall, PharmD, BCOP

Clinical Coordinator
Bleeding Disorders/Hematology
Atrium Health Specialty Pharmacy Service
Atrium Health
Charlotte, North Carolina

Justin Arnall, PharmD, BCOP, has disclosed that he has received consultant/advisor/speaker fees from CTI Biopharma and Novo Nordisk.
Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kayla Douglas, PharmD, has disclosed that she has received consultant/ advisor/speaker fees from Bayer, Biomarin, Freeline, and Pfizer.

Staff

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pharmacists, managed care professionals, and other healthcare professionals who care for patients with hemophilia.

Goal

The goal of this activity is to educate pharmacists and managed care professionals about advances in the use of novel curative and noncurative therapeutic options for patients with hemophilia A.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-142-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 24, 2022, through May 23, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Pharmacy Perspectives for Tailoring Hemophilia A Prophylaxis: Review of Current and Evolving Treatments

Loading...
Watch this on-demand webcast of a live CCO webinar to gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies.
person default
Justin Arnall, PharmD, BCOP
person default
Kayla Douglas, PharmD
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 24, 2022 Expiration: May 23, 2023

Related Content

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of hemophilia A with nonfactor replacement therapies

person default Kayla Douglas, PharmD Released: April 27, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings